News

AcuCort’s application for ethical review for a questionnaire study on allergy treatment is approved

8 juni, 2022

AcuCort AB (publ) (Spotlight Stock Market: ACUC) announces today that the Swedish Ethical Review Authority has approved the... [Läs mer]

AcuCort applies for ethical review for a questionnaire study on allergy treatment

26 april, 2022

AcuCort AB (publ) (Spotlight Stock Market: ACUC) announces today that the company has submitted an ethical review application... [Läs mer]

AcuCort publishes the Annual Report for 2021

12 april, 2022

AcuCort AB (publ) (Spotlight Stock Market: ACUC) hereby announces that the company’s Annual Report for the financial year... [Läs mer]

Changed date for Annual General Meeting in AcuCort

23 mars, 2022

AcuCort AB (publ) (Spotlight Stock Market: ACUC) announces that the Annual General Meeting 2022 will be held on... [Läs mer]

AcuCort is exempted from the application fee by the U.S. Food and Drug Administration

1 mars, 2022

AcuCort AB (publ) (Spotlight Stock Market: ACUC) announces today that the U.S. Food and Drug Administration, FDA, grants... [Läs mer]

AcuCort enters agreement with the pharmaceutical manufacturer Adhex Pharma regarding commercial and large-scale production of ISICORT®

22 februari, 2022

AcuCort AB (publ) (Spotlight Stock Market: ACUC) announced today that the company has signed an agreement with the... [Läs mer]

AcuCort announces that the company signs an agreement with consulting company in pharmacovigilance before the upcoming commercialization of ISICORT®

17 februari, 2022

AcuCort AB (publ) (Spotlight Stock Market: ACUC) announced today that the company has signed an agreement with the... [Läs mer]

AcuCort announces that the registration process in the Nordic market is underway for the company’s drug ISICORT®

15 november, 2021

AcuCort AB (Spotlight Stock Market: ACUC) announced today that the registration process in Denmark, Finland, Iceland and Norway... [Läs mer]

AcuCort’s drug ISICORT® demonstrates a three-year shelf life

5 oktober, 2021

AcuCort AB (Spotlight Stock Market: ACUC) today announced that the company’s drug ISICORT® has demonstrated a three-year shelf... [Läs mer]

AcuCort receives a second US patent protection for its drug ISICORT®

3 september, 2021

AcuCort AB (Spotlight Stock Market: ACUC) today announces that the US Patent and Trademark Office, USPTO, has announced... [Läs mer]